Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Phase 2 Study of Amivantamab, Lazertinib and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers (NSCLCs) With EGFR Mutations

NCT05299125 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.

NCT NCT05299125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05299125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Phase 2 Study of Amivantamab, Lazertinib and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers (NSCLCs) With EGFR Mutations
Lead sponsor
Latin American Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
May 24, 2023
Completion date
November 21, 2025
Enrollment
54 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancers